Backgrounds/Aims: To compare the clinical outcomes of intraoperative radiofrequency ablation (RFA) and non-anatomical hepatic resection (NAHR) for small hepatocellular carcinoma (HCC). Methods: From February 2007 to January 2015, clinical outcomes of thirty four patients with HCC receiving RFA or NAHR were compared, retrospectively. Results: There was no difference of patient and tumor characteristic between the two groups that received RFA or NAHR. The 1, 2, and 3-year recurrence rates following RFA were 32.2%, 32.2% and 59.3% respectively, and 6.7%, 33.3% and 33.3% following NAHR respectively (p=0.287). The 1, 2 and 3-year overall survival (OS) rates following RFA were 100%, 88.9% and 76.2% respectively, and 100%, 85.6% and 85.6%, respectively, following NAHR (p=0.869). We did not find a definite statistical difference in recurrence rate and OS rate between the two groups. In the multivariate analysis, number of tumor was an independent prognostic factor for recurrence and albumin was an independent prognostic factor for OS. Conclusions: We recommend non-anatomical hepatic resection rather than intraoperative RFA in small sized HCC, due to a higher recurrence rate in intraoperative RFA. Intraoperative RFA was inferior to non-anatomical hepatic resection in terms of recurrence rate. We need to select the optimal treatment considering liver function and possibility of recurrence. 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most frequent primary hepatic malignancy. 1 Hepatic resection and liver transplantation is recommended by the latest guidelines for early HCC, meeting the Milan criteria with the 5-year survival rate potentially reaching 50 to 75%. 2, 3 However, a limited number of patients can be treated with liver transplantation due to its strict indication, high cost and limited donor liver availabiity. 4 Generally, anatomical hepatic resection is preferred when treating HCC because HCC has a tendency to invade the portal veins and spread along intrasegmental branches. 5 Few patients however are suitable for liver resection because of poor liver function 6 such as cirrhosis, chronic liver disease and the difficulty in predicting postoperative liver failure. Non-anatomical hepatic resection (NAHR) is an attractive alternative treatment option for patients with cirrhotic liver limiting resectability of liver.
It has been previously reported that non-anatomical resection is equal to anatomical resection, and in some cases non-anatomical hepatic resection is recommended over anatomical resection. 7, 8 Radiofrequency ablation (RFA), which is one of the local ablative techniques, was reported to be effective in achieving complete tumor necrosis. RFA is currently used for treating resectable small HCC. 9 Although the effectiveness is less well established than hepatic resection, RFA has been widely accepted for treating patients with unresectable HCC. 7 RFA is an attractive treatment due to its advantages over liver resection, including a reduced destruction of normal liver tissue, lower cost, lower complication rate, and shorter hospital stay. 10, 11 In spite of this, there is still debate over whether RFA or Hepatic resection is the most suitable therapy for This study aims to compare the effectiveness of RFA and NAHR, especially the short term results, for small sized HCC retrospectively. 
MATERIALS AND METHODS

Procedure and indication of RFA
RESULTS
Patient & tumor characteristics
The demographics and clinical characteristic are summarized in Tables 1 and 2 . The NAHR group was younger in mean ages (58.6 vs. 64.8 years; p=0.003) and had Comparison of the recurrence and overall survival rates The recurrence rate at 1, 2 and 3 years were 32.2%, 32.2% and 59.3% respectively in the RFA group, and 6.7%, 33.3% and 33.3% respectively in the NAHR group (p=0.287) (Fig. 2) . In univariate analysis, PT INR, MELD score, and tumor number were predictors of tumor recurrence (p=0.003, p=0.001, p=0.007, respectively) ( Table   3 ). In multivariate analysis, tumor number was a predictor of recurrence (p=0.019) ( Table 4 ). The OS rates at 1, 2 and 3 years were 100%, 88.9% and 76.2% respectively in the RFA group, and 100%, 85.6% and 85.6% respectively in the NAHR group (p=0.869) (Fig. 3) . In univariate analysis, albumin and PT INR were predictors of overall survival (OS) (p=0.004 and p=0.023, respectively) (Table 3) . In multivariate analysis, albumin was a predictor of recurrence rate (p=0.020) ( Table 4) .
DISCUSSION
HCC is the most frequent primary hepatic malignancy and, with the advance of diagnostic imaging modality, the diagnosis of small HCC has improved considerably. It has allowed patients to have the opportunity to cure HCC by hepatic resection or local ablation, for example using RFA. 1, 12, 13 However, many clinicians find it difficult to select the optimal therapy and treatment for individual patients with HCC. Although hepatic resection is considered the treatment of choice for HCC, many factors, including liver dysfunction, general condition of the patient and tumor location, and portal vein invasion of tumor, often limit the indication for hepatic resection and extent of treatment. 14, 15 Under such circumstances, NAHR or RFA could be appropriate treatments for small sized HCC.
To date there has been no study comparing NAHR and RFA to determine which is the better treatment for patients with small HCCs. Several randomized controlled trials (RCT) have compared the efficacy of hepatic resection and RFA. Imai et al. concluded that in 2-3 cm HCC, hepatic resection would be the first-line therapy because of an observed higher survival rate and lower recurrence rate. 16 Wang et al. 17 reported that for HCC patients in the BCLC very early/early stage, surgical resection yielded better disease-free survival rate than RFA.
However, in these RCTs, non-anatomical hepatic resection and anatomical hepatic resection, and percutaneous RFA and intraoperative RFA, were not distinguished. In our study, we compared the survival rates between NAHR and intraoperative RFA in patients with HCC less than 3 cm.
Of course these patients were treated with the intension to treat.
In this situation, the different recurrence rates between the two groups could be related to differences in background characteristics, especially liver function related factors. The result of high recurrence and low OS rate in the NAHR may be the result of liver function, as liver function is related to liver fibrosis, and liver fibrosis is associated with a high risk of multi-centric carcinogenesis. 18 As such prothrombin activity, albumin, total bilirubin, and
Child-Pugh class could be the strongest predictors. [19] [20] [21] [22] [23] [24] [25] [26] To equalize these variables of the two groups, we used the propensity score matching method. In this study, OS and recurrence rates of NAHR surpassed those of intraoperative RFA group, except after 2-years when OS and recurrence rates were not significantly different between the two groups. This result may be explained by initial small scale cohorts. the non-anatomic group were 21%, 52%, and 76%
respectively. The 1, 3, and 5-year OS rates in the non-anatomic group were 97%, 91%, and 61% respectively.
Okamura et al. 30 compared the disease-free survival and OS rates using propensity matching analysis in the non-anatomic resection group and found that the cumulative 1, to small sample size, and short-term follow-up study.
Although, without statistically significant differences, liver function-related factors, including PT INR, albumin, total bilirubin, and grading systems (Child-Pugh class and MELD score) also seems to be a prognostic factor of overall survival rate and recurrence rate. This suggests that the severity of the underlying liver disease may be a risk factor of HCC recurrence and overall survival. It also supports the importance of liver status in carcinogenesis.
HCC patients with low levels of AFP and PIVKA-II had more favorable clinical characteristics and showed a better prognosis than those with elevated levels of AFP or PIVKA-II. 32 We found that tumor markers were not related to tumor recurrence or OS. We attempted to evaluate the tumor markers for each patient before operation, but some patients were missing. Additionally, we checked PIVKA-II for preoperative patients but could only gather a small data set.
Our study had several limitations. First of all, our study included a small sample size and short follow-up period.
We think that this accounts for the absence of statistically significant differences. Secondly, it was a retrospective study. Thus, our study has fundamental flaws by a selection bias. We overcame selection bias by using propensity score matching methods, but it made a result from a smaller sample size.
In this study, the tumor number is a predictor of disease free survival and albumin is a predictor of overall survival in small sized HCC patients. We recommend non-anatomical hepatic resection over intraoperative RFA in small sized HCC, because of high recurrence rate in intraoperative RFA. We did not find intraoperative RFA to be inferior to NAHR in any other way, except recurrence rate. Clinicians need to select the optimal treatment considering liver function and possibility of recurrence. Our study highlights the requirement for a large volume long-term follow-up study to further analyze these treatments and when they are best applied.
